ELIAS JOSEPH JABBOUR to Patient Selection
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Patient Selection.
Connection Strength
0.388
-
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):323-34.
Score: 0.298
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.090